SARTORIUS STEDIM BIOTECH (56S1.DE) Fundamental Analysis & Valuation

FRA:56S1 • FR0013154002

Current stock price

167.05 EUR
+4.55 (+2.8%)
Last:

This 56S1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. 56S1.DE Profitability Analysis

1.1 Basic Checks

  • 56S1 had positive earnings in the past year.
  • In the past year 56S1 had a positive cash flow from operations.
  • 56S1 had positive earnings in each of the past 5 years.
  • In the past 5 years 56S1 always reported a positive cash flow from operatings.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • 56S1 has a worse Return On Assets (3.33%) than 68.42% of its industry peers.
  • 56S1 has a worse Return On Equity (6.50%) than 63.16% of its industry peers.
  • 56S1's Return On Invested Capital of 6.11% is in line compared to the rest of the industry. 56S1 outperforms 52.63% of its industry peers.
  • 56S1 had an Average Return On Invested Capital over the past 3 years of 5.23%. This is below the industry average of 9.20%.
  • The 3 year average ROIC (5.23%) for 56S1 is below the current ROIC(6.11%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROIC 6.11%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • 56S1 has a Profit Margin (8.96%) which is in line with its industry peers.
  • In the last couple of years the Profit Margin of 56S1 has declined.
  • 56S1's Operating Margin of 17.72% is in line compared to the rest of the industry. 56S1 outperforms 57.89% of its industry peers.
  • 56S1's Operating Margin has declined in the last couple of years.
  • 56S1 has a Gross Margin (45.33%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of 56S1 has declined.
Industry RankSector Rank
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. 56S1.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 56S1 is destroying value.
  • The number of shares outstanding for 56S1 remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, 56S1 has more shares outstanding
  • The debt/assets ratio for 56S1 has been reduced compared to a year ago.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 3.82 indicates that 56S1 is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 56S1 (3.82) is better than 78.95% of its industry peers.
  • The Debt to FCF ratio of 56S1 is 8.69, which is on the high side as it means it would take 56S1, 8.69 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of 56S1 (8.69) is comparable to the rest of the industry.
  • 56S1 has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.49, 56S1 is in line with its industry, outperforming 57.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Altman-Z 3.82
ROIC/WACC0.66
WACC9.26%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • 56S1 has a Current Ratio of 1.02. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.02, 56S1 is doing worse than 68.42% of the companies in the same industry.
  • A Quick Ratio of 0.53 indicates that 56S1 may have some problems paying its short term obligations.
  • 56S1 has a Quick ratio of 0.53. This is in the lower half of the industry: 56S1 underperforms 73.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.53
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. 56S1.DE Growth Analysis

3.1 Past

  • 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
  • 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.13% yearly.
  • The Revenue has been growing slightly by 6.74% in the past year.
  • Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 9.21% on average per year.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.04% on average over the next years. This is quite good.
  • 56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.26% yearly.
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. 56S1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 37.97, the valuation of 56S1 can be described as expensive.
  • Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than 78.95% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (25.71), we can say 56S1 is valued slightly more expensively.
  • With a Price/Forward Earnings ratio of 31.74, 56S1 can be considered very expensive at the moment.
  • 56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 78.95% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of 56S1 to the average of the S&P500 Index (23.83), we can say 56S1 is valued slightly more expensively.
Industry RankSector Rank
PE 37.97
Fwd PE 31.74
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 78.95% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, 56S1 is valued a bit more expensive than the industry average as 63.16% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 54.38
EV/EBITDA 21.79
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • 56S1's earnings are expected to grow with 19.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.94
PEG (5Y)33.65
EPS Next 2Y19.98%
EPS Next 3Y19.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 56S1.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.43%, 56S1 is not a good candidate for dividend investing.
  • The stock price of 56S1 dropped by -21.68% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • 56S1's Dividend Yield is comparable with the industry average which is at 0.54.
  • Compared to an average S&P500 Dividend Yield of 1.91, 56S1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.43%

5.2 History

  • On average, the dividend of 56S1 grows each year by 15.19%, which is quite nice.
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 56S1 pays out 25.24% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.24%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

56S1.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS STEDIM BIOTECH

FRA:56S1 (3/12/2026, 7:00:00 PM)

167.05

+4.55 (+2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)N/A
Inst Owners11.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.26B
Revenue(TTM)2.97B
Net Income(TTM)265.80M
Analysts78.95
Price Target247.39 (48.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.43%
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.24%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.48%
Min EPS beat(2)-12.72%
Max EPS beat(2)-2.24%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-12.72%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.28%
EPS beat(12)3
Avg EPS beat(12)-11.72%
EPS beat(16)3
Avg EPS beat(16)-14.26%
Revenue beat(2)0
Avg Revenue beat(2)-4.06%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-3.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.07%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.65%
Revenue beat(12)5
Avg Revenue beat(12)-1.63%
Revenue beat(16)6
Avg Revenue beat(16)-1.17%
PT rev (1m)0.22%
PT rev (3m)2.79%
EPS NQ rev (1m)-0.96%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-1.16%
Revenue NQ rev (1m)-5.86%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.14%
Revenue NY rev (3m)-2.98%
Valuation
Industry RankSector Rank
PE 37.97
Fwd PE 31.74
P/S 5.48
P/FCF 54.38
P/OCF 23.49
P/B 3.97
P/tB N/A
EV/EBITDA 21.79
EPS(TTM)4.4
EY2.63%
EPS(NY)5.26
Fwd EY3.15%
FCF(TTM)3.07
FCFY1.84%
OCF(TTM)7.11
OCFY4.26%
SpS30.49
BVpS42.03
TBVpS-3.39
PEG (NY)1.94
PEG (5Y)33.65
Graham Number64.5
Profitability
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROCE 8%
ROIC 6.11%
ROICexc 6.56%
ROICexgc 23.58%
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
FCFM 10.08%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Debt/EBITDA 2.39
Cap/Depr 123.61%
Cap/Sales 13.25%
Interest Coverage 3.42
Cash Conversion 82.03%
Profit Quality 112.49%
Current Ratio 1.02
Quick Ratio 0.53
Altman-Z 3.82
F-Score7
WACC9.26%
ROIC/WACC0.66
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%
EBIT growth 1Y41.93%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year55.74%
EBIT Next 3Y26.51%
EBIT Next 5Y22.89%
FCF growth 1Y-37.09%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y-15.08%
OCF growth 3Y4.17%
OCF growth 5Y10.67%

SARTORIUS STEDIM BIOTECH / 56S1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 0 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for 56S1 stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 37.97 and the Price/Book (PB) ratio is 3.97.


What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?

The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 19.6% in the next year.